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Philanthropists are exerting an unmistakable influence on the research agenda, drawing 
attention to long-ignored research areas, promoting collaborations, and giving scientists 
the freedom to explore serendipitous ideas. Unbridled by politics or bureaucracy, philan-
thropic organizations can fund the riskier projects that could yield the biggest payoffs.With RO1 individual investigator grants 
from the National Institutes of Health 
(NIH) becoming more difficult to 
obtain, researchers are seeking fresh 
sources of funding from philanthropic 
organizations. “We’re starting to bleed 
here at the University of Washing-
ton. Postdocs and technicians are 
being laid off,” says George Martin, 
who studies aging. His institution is 
not alone. “It’s happening all over the 
country. High-impact research insti-
tutes thrive on soft money and they’re 
hit the hardest,” says Martin, who 
receives funding from the Alzheimer’s 
Association and the M.J. Murdock 
Charitable Fund. “I don’t see the pos-
sibility of any substantial increases in 
[NIH funding] so the money will have 
to come from private sources.”
Funding Risky Research, Forging 
New Collaborations
Traditional NIH grants usually fund rig-
idly defined projects, whereas funds 
from philanthropic organizations can 
give scientists the freedom to under-
take risky research and to forge ambi-
tious collaborations. For example, the 
ability to join talented people together 
to tackle large-scale research projects 
is a defining strength of the Broad Insti-
tute in Cambridge, Massachusetts. The 
Institute’s philanthropic backers, Eli 
and Edythe L. Broad, initially provided 
$100 million, to be spent at the rate of 
$10 million per year for 10 years, and 
then soon doubled this gift to $200 mil-
lion. The Institute’s 114 faculty consist 
of 6 core members, who are located 
at the Broad Institute, and 108 associ-
ate members whose primary labs are 
located at other world-class biomedical 
facilities in the area. These facilities are 
often referred to as vertical silos, says 
Eric Lander, founding director of the 
Broad Institute and a professor at MIT, 
Harvard Medical School, and the White-head Institute for Biomedical Research. 
“There are all the departments at MIT, 
all the departments at Harvard, the 
medical school, the school of public 
health, the teaching hospital, etcetera, 
and the Broad is a horizontal connec-
tor between all of those,” says Lander. 
Although the Broad funds constitute a 
minority of the Institute’s budget, “The 
Broad funds are what make the Broad 
possible,” says Lander. He says that 
while the NIH system forms the back-
bone of biomedical research, it’s nec-
essarily conservative and, “We need 
other sources of funds that are not 
conservative.” Lander calls the Broad 
funding “academic venture funds to 
try experiments.” “We’re doing experi-
ments on how to do science,” says 
Lander. “Broad is an experiment that 
says we should take risks on building 
datasets that might fail.” As an exam-
ple, Lander points to the connectivity 
map spearheaded by Todd Golub, the 
director of the Broad Institute’s Cancer 
program. The map is a database of the 
genetic signatures of various drugs, 
“You take drugs, put them on cell lines, 
look at their whole expression pattern 
and make a database. It turns out that 
by doing that you can take up all sorts 
of connections between drugs that you 
never knew—that drug X might be use-
ful for disease Y because of its expres-
sion pattern,” says Lander. “If you went 
to a study section and told them you 
want to develop this kind of database, 
they’d say, what a fishing expedition. 
This is the sort of project we use Broad 
funds for.” The Institute also fosters 
creativity with its Scientific Planning 
and Allocation of Resources Com-
mittee (SPARC). SPARC proposals 
have been funded for small amounts 
like $40,000 or for $1 million or more, 
says Lander. “They can move rapidly 
because the death knell of creativity is 
to tell a young scientist that she should Cell 128, Fwrite a grant proposal for her great idea 
and three years later get the money to 
try it,” says Lander.
The Broad Institute isn’t the only 
philanthropic organization to encour-
age young scientists to aim high. The 
John D. and Catherine T. MacArthur 
Foundation, one of the largest private 
philanthropic foundations in the US, 
fosters progress by identifying the 
very brightest, most creative minds 
in all disciplines and providing them 
with resources to help them live up to 
their potential. In September last year, 
Kevin Eggan, an embryonic stem cell 
researcher at the Harvard Stem Cell 
Institute, received a phone call inform-
ing him that he’d been awarded one of 
the MacArthur Foundation’s so-called 
“genius” grants—$500,000 over 5 
years to spend in any way he sees 
fit. MacArthur fellows are nominated 
and selected anonymously and are 
chosen for their potential rather than 
for their prior successes. “[The fellow-
ship] provides flexibility to do things 
that I wouldn’t otherwise be able to 
do,” says Eggan. “The MacArthur 
foundation is a very forward thinking, 
thoughtful organization; to give us this 
award means they’ve thought deeply 
about stem cell research,” he says.
Embryonic stem cell research and 
other controversial or politically sensi-
tive research areas are heavily depend-
ent on philanthropic funding for their 
survival. Because US federal funds 
cannot be used to support embryonic 
stem cell research, private philanthro-
pists are stepping in to fill the gap. The 
Charles C. and June S. Gates Family 
Fund trustees recently committed $6 
million to the University of Colorado at 
Denver and the Health Sciences Center 
to establish the Charles C. Gates 
Regenerative Medicine and Stem Cell 
Biology Program. Meanwhile, in Califor-
nia, the Dolby Foundation (founded by ebruary 9, 2007 ©2007 Elsevier Inc. 421
sound pioneer Ray Dolby of Dolby Lab-
oratories) donated $5 million to ensure 
that stem cell research at the fledgling 
California Institute for Regenerative 
Medicine (CIRM) could move forward, 
after public funds were blocked by a 
court challenge.
Patients Boost Funds for  
Biomedical Research
Cancer survivors Jim and Virginia 
Stowers, founders of American Cen-
tury Investments, created the Stowers 
Institute for Medical Research in 2000 
with a very focused mission to support 
basic research on cell proliferation, dif-
ferentiation, and cell death during early 
development. The Institute, housed 
on a 10-acre campus in Kansas City, 
Missouri, offers its scientists state of 
the art technical support with access 
to advanced imaging systems, trans-
genic animal and microarray facilities, 
and other costly infrastructure. “We 
allow our researchers to rely on a very 
strong base of support to undertake 
risky experiments that would never 
attract funding from the NIH or from 
any other rather risk averse funding 
agency,” says reproductive endo-
crinologist William Neaves, President 
and CEO of the Stowers Institute. “We 
can tell people that if you come here, 
we will make sure you will have a high 
level of collaborative support from 
one of the best proteomics facilities in 
the world and access to a tech center 
with state of the art mass spectrom-
eter facilities,” says Neaves. “We offer 
those who join us here a collabora-
tive environment that offers them an 
opportunity to do more important 
work than any of them can do alone.”
Philip Kantoff, chief clinical research 
officer at the Dana Farber Cancer Insti-
tute in Boston, has received numerous 
donations from grateful patients as well 
as from private groups like the Pros-
tate Cancer Foundation (founded by 
prostate cancer survivor and billionaire 
Michael Milken). Kantoff says he’s had 
some patients write him a check and 
say “here’s some money to spend on 
research,” but he’s also had philan-
thropists approach and say, “here’s 
my foundation, let’s see if we can get 
you a grant.” Some patients send in 
small donations, but in one instance 422 Cell 128, February 9, 2007 ©2007 Elhe received $5 million for his research. 
This charitable money gives Kantoff 
the freedom to support innovative can-
cer research in his lab and others at 
the Dana Farber. NIH grants pay for the 
specific project proposed in the grant, 
but nothing more—there’s no extra 
money in the grant to pay for stepping 
out of the box and that’s where the 
exciting work happens, says Kantoff.
Often an exciting result leads a 
researcher beyond the realm of a nar-
rowly defined project, and it might take 
months or years for a scientist to apply 
for and receive the additional funding 
necessary to pursue the promising 
lead. The Michael J. Fox Foundation, 
which funds research on Parkinson’s 
disease, is hoping to speed up this 
process with its new Rapid Response 
Innovation Awards. The grants of up to 
$75,000 are meant to allow researchers 
to quickly access the funds they need 
to follow through on new ideas. “It’s 
a three-page grant application,” says 
Eugene M. Johnson, Jr., chief scientific 
advisor at the Michael J. Fox Foun-
dation. “You send us the grant, we’ll 
review it on a rolling basis and get back 
to you within six weeks.” The organi-
zation’s founder, the Hollywood actor 
Michael J. Fox, began his eponymous 
foundation after he was diagnosed in 
his thirties with Parkinson’s disease.
A Long Tradition of  
Philanthropically Funded Research
The Michael J. Fox Foundation is not 
the only biomedical philanthropy with 
ties to Hollywood. Created in 1953 
by the famous industrialist and movie 
producer Howard Hughes, the Howard 
Hughes Medical Institute (HHMI) has 
been a driving force in the US biomedi-
cal research community for more than 
50 years. “We believe in funding peo-
ple not projects,” says HHMI president 
Thomas Cech. “Our philosophy is to 
pick the best people and give them a 
lot of flexibility and autonomy,” says 
Cech. The Institute spent $483 mil-
lion on scientific research in 2005 and 
holds regular competitions to seek new 
investigators, who receive funding for 5 
years. After those first 5 years, Hughes 
investigators are required to report 
back on what they’ve done, “So there 
is a day of reckoning, but there’s a long sevier Inc.period of quite dramatic freedom until 
then,” say Cech. “We enable creativity 
by not being so hands on,” says Cech. 
“The more constrained the funding of a 
project is, the more likely it will result in 
incremental increases in knowledge in 
an established field, which is not bad, 
but it’s unlikely to completely change 
the way people think about science.” 
Cech says HHMI will never become a 
substitute for the NIH but, rather, strives 
to compliment it. “The strong NIH in 
our country gives a nonprofit institute 
like us the opportunity and, we would 
say, the responsibility to not just add 
incrementally to governmental funding 
but to do something that cuts across 
the opportunities in a completely differ-
ent direction,” he says.
Across the Atlantic, Britain’s Well-
come Trust, established in 1936 by Sir 
Henry Wellcome, also aims to support 
talented scientists so that they can 
undertake riskier research projects. 
“We make a difference by making brave 
grants to the very best people in the 
best places and not being risk averse,” 
says Wellcome Trust director Mark 
Walport. “Good science is about ask-
ing important questions, and we fund 
the people who have important things 
to ask,” says Walport. With a budget 
approximately twice that of HHMI, the 
Wellcome Trust is perhaps Europe’s 
most influential biomedical funding 
agency and will spend approximately 
£540 million (US $1066 million) in 2007 
to support 3500 researchers in 44 
countries. Past projects the Trust has 
supported include everything from the 
human genome project to the develop-
ment of the malaria drug artemisinin.
The Wellcome Trust provides roughly 
half of the UK’s biomedical research 
funding and thus plays a crucial role in 
keeping the research enterprise going. 
Cech says that gives the Wellcome 
Trust a level of responsibility that the 
HHMI doesn’t face. “If you’re half of the 
total funding you can’t say, ok, we’re 
only going to fund bioengineers next 
year, because it would leave a lot of 
really strong work abandoned,” he says. 
Even so, the Wellcome Trust does not 
try to substitute for public funding, and 
it specifically looks beyond the type of 
research that governments might sup-
port, says Walport. “We can ask diffi-
cult questions,” he says. “We can act 
as an independent voice of reason in 
politically contentious areas,” he says. 
For example, at the beginning of the 
HIV epidemic it wasn’t clear how the 
disease was transmitted. “We funded 
a survey of young people’s sexual hab-
its—something the government at the 
time wasn’t keen to do,” says Walport.
But Europe is not depending solely 
on the largesse of the Wellcome Trust. 
Last March, philanthropy experts and 
researchers from throughout Europe 
gathered for a conference in Brussels 
entitled, “Giving More For Research in 
Europe: Strengthening the Role of Phi-
lanthropy in the Financing of Research.” 
During the conference, Janez Potocnik, 
European commissioner for research, 
told attendees that, without ques-
tion, philanthropic giving for research 
remains underdeveloped in most Euro-
pean countries. With the exception 
of the UK, most European nations do 
not have a strong culture of charitable 
giving for research, he said in a key-
note speech. “We need to create an 
environment where giving is regarded 
positively by both donor and recipient.” 
According to Potocnik, achieving this 
will require both a change in culture as 
well as tax credits and other govern-
ment incentives for donors.
Money Can Come (and Go) Quickly
The ability to deliver money quickly 
is a hallmark of philanthropic groups. 
While red tape can make the proc-
ess of procuring government funding 
a slow process, philanthropists can 
make speedy decisions, especially in 
the face of a pressing need. “We can 
move very, very quickly when we need 
to,” says Richard Sprott, executive 
director of the Ellison Medical Foun-
dation. As an example, he points to 
the anthrax scare in the US following 
the 9/11 attacks. Researchers wanted 
to find out what the background level 
of anthrax was in US post offices. “It 
would have taken the NIH years to 
find out. We called up an expert and 
had him funded in six weeks, and had 
an answer in six months.”“We fund many of the same peo-
ple as the NIH does, but we can 
fund them for a new idea much more 
quickly than the NIH can,” says Sprott. 
“It generally takes us less than six 
months from the grant application to 
the award.” Still, such speed can also 
prove a minus, says Sprott. “We can 
just as easily take away the money. 
If we see a program isn’t working 
we can end it.” Indeed, in 2005, the 
Ellison Foundation halted its global 
infectious diseases program after 
deciding that they were not making 
enough of a difference in that field.
And then there’s the insecurity inher-
ent in taking funds from a single phi-
lanthropist. “We exist as long at Larry 
Ellison wants us to. He can pick up the 
phone and say it’s over and it’s over,” 
says Sprott. Though Sprott says the 
Foundation looks safe at the moment, 
there’s no guarantee. Ellison, the 
cofounder of the software corporation 
Oracle, was required to give $100 mil-
lion to his foundation as part of a set-
tlement with stockholders and recently 
cancelled a $115 million gift to Harvard 
University following the resignation of 
University president Larry Summers.
Many of today’s donors are apply-
ing more scrutiny to their grantees 
than previous generations did, says 
Andrew Hastings, vice president of 
the National Philanthropic Trust in 
Jenkintown, Pennsylvania. “Donors 
are taking a more active role in their 
philanthropy, and expecting greater 
results. A generation ago, donors were 
more likely to support causes with 
unrestricted gifts. Now more donors 
are being more selective and specific 
with their grant-making.” Lee-Ann 
Coleman, head of policy research at 
the Association of Medical Research 
Charities in London, has also seen 
this trend in the UK, and she says 
that many charities there are playing 
an active role in how research results 
are disseminated and applied. “The 
old fund and forget mentality is gone,” 
says Mary Maxon, deputy vice chair of 
CIRM. “If they want something done, 
they’re willing to pay for it, but they’re Cell 128, Fnot just going to give the money and 
walk away.”
Some private organizations are 
moving to outcome-driven models. 
“The new funders don’t just want 
to support research, they want to 
be partners in it,” says Susan Fitz-
patrick, vice president of the James 
S. McDonnell Foundation in Saint 
Louis, Missouri. Founded in 1950 by 
aerospace pioneer James S. McDon-
nell, the Foundation awarded $15.5 
million worth of grants in 2004, much 
of it for research on neuroscience 
and brain cancer. Fitzpatrick says 
that today many foundations like hers 
are bringing patients, advocates, and 
clinicians into the decision-making 
process and they want to see tangible 
results. “This is not a basic science 
research institute. Some models that 
people study have no relevance to 
human disease and we’re not going 
to fund those,” says Fitzpatrick. “We 
gave three $2 million grants, which is 
a lot for a voluntary health organiza-
tion, and we want a say in how the 
work gets done,” says Fitzpatrick.
But success in raising research 
funds from philanthropic donors and 
foundations could come with a price. 
With philanthropic giving rising at an 
annual rate of six percent in the US, 
according to the National Philan-
thropic Trust, and a drive to bolster 
charitable giving in Europe, some 
worry that an influx of philanthropic 
money could lead governments to 
hand responsibility for biomedical 
research to the private sector. “You 
do worry about becoming an enabler 
and we hear anecdotally that that’s 
happening,” says Sprott. However, 
despite the start of the new Congress 
this month, US federal funding for 
R&D for FY2007 remains in limbo, 
and the NIH budget remains flat and 
may even fall. This situation provides 
a stark reminder that political tides 
and government budgets are con-
stantly shifting, and that philanthro-
pists will continue to play a key role in 
funding risky cutting-edge research 
for the foreseeable future.
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